1. Introduction {#s0005}
===============

Despite over a century of data driven education, research, and elimination efforts ([@bb0255]), malaria claimed 405,000 lives in 2018 when 228 million cases of infection were recorded worldwide ([@bb0445]). Botswana accounted for a very small fraction of these mortalities and infections, 9 and 879, respectively, in the same year ([@bb0445]). These numbers are extraordinary in comparison to previous estimations from the early 2000s, where annual malaria cases in Botswana frequently exceeded 70,000 ([@bb0430]) in a population of 2.3 million. A change in focus from a program solely concentrated on vector control, to one that had improved access to diagnostic tools, initiation of contact tracing, free distribution of insecticidal nets in specific endemic regions in conjunction with indoor residual spraying (IRS), and access to free antimalarial chemotherapy circa 2010 by Botswana\'s Ministry of Health ([@bb0235]; [@bb0430]), greatly reduced the country\'s malaria burden ([Fig. 1](#f0005){ref-type="fig"} ). This allowed the country to adopt a national malaria elimination strategy in 2009 and attain the targets therein over several years ([@bb0320]). Despite these major improvements, the World Health Organization (WHO) has raised concerns about the epidemic propensity of malaria in Botswana and in other southern African countries. During the 2016/2017 malaria season, Botswana experienced an 80% increase in annual malaria cases, which mirrored intensified transmission in other southern African countries ([@bb0440]).Fig. 1Map of Africa showing Botswana\'s geographical position and malaria cases over an 18 year period. Years 2000--2013 ([@bb0430]), 2014--2018 ([@bb0445]).Fig. 1

1.1. Country profile {#s0010}
--------------------

Botswana is a landlocked country that is surrounded by Namibia, Zambia, Zimbabwe, and South Africa. It is comprised of large swaths of desert, such as the Kgalagadi, as well as the world renowned Okavango Delta. Temperatures in the summer can rise above 45 °C and sub-freezing temperatures are occasionally noted in the winter months of June--August. Rainfall ranges between 650 mm in the Northern portions of the country, to 250 mm in the extreme Southern sections of the Kgalagadi ([@bb0395]). Although rainfall usually occurs between November and April, Botswana is vulnerable to intermittent and periodic drought ([@bb0395]) associated with the El Niño Southern Oscillation (ENSO) pattern.

Malaria transmission in Botswana is seasonal and highly unstable. Transmission typically occurs between November and April during the rainy season when extreme flooding creates prime breeding grounds for malarial vectors ([@bb0320]). Peak malaria transmission usually occurs in March--April due to increased rainfall and temperatures in the previous months ([@bb0395]). Spatial-statistical models have identified summer rainfall, mean annual temperature and altitude to be the main environmental predictors of malaria risk in Botswana, which explains the annual fluctuations registered in the last years ([@bb0100]). These environmental variables make the more South and Southeastern regions prone to fluctuating levels of transmission and sporadic epidemics ([@bb0040]; [@bb0100]). Whereas, malaria in the Northwestern region is considered endemic with sustained transmission annually ([@bb0430]). Malaria incidence in the region increases during La Niña Southern Oscillations episodes, and decreases with El Niño, despite some incongruences ([@bb0100]; [@bb0185]).

Of the five *Plasmodium* species known to infect humans (*Plasmodium falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi*), *P. falciparum* is the primary species responsible for morbidity and mortality in sub-Saharan Africa ([@bb0445]) and Botswana. However, recent surveys have demonstrated a much higher prevalence of *P. vivax* in Botswana than previously expected, which is congruent with findings in neighboring countries ([@bb0035]; [@bb0155]; [@bb0245]). Like many countries in the Southern Africa Development Community (SADC), *Anopheles arabiensis* has been demonstrated to be a major vector spreading malaria in Botswana ([@bb0040]). However, multiple studies have found several other malaria vectors in Botswana which have received little to no national attention, likely due to the fact that they have not been found to carry *Plasmodium* within the country\'s borders ([@bb0005]; [@bb0095]; [@bb0185]; [@bb0190]; [@bb0210]; [@bb0290]; [@bb0375]). Though, variances in collection techniques, mosquito species screenings and whether trapped mosquitoes were tested for sporozoites may have impacted evidence of their vectorial capacity in the country.

1.2. Demographics {#s0015}
-----------------

Botswana houses approximately 2.3 million individuals of a unique genetic background ([@bb0350]). Nearly 1.5 million of these residents are at risk for malarial infection ([@bb0445]), with the highest incidence found in the northern part of the country ([Fig. 2](#f0010){ref-type="fig"} ). Khoisan and Bantu are the two major ancestral groups of today\'s Botswana people. Admixture has occurred between the two ethnic groups to various extents ([@bb0335]). As a consequence, there is a wider spectrum of genotypes and phenotypes when considering genetic characteristics such as Duffy antigen, sickle cell trait, glucose-6-phosphate dehydrogenase (G6PD), and detoxifying liver enzymes ([@bb0150]; [@bb0250]; [@bb0380], [@bb0385]). These human genetic factors play a pivotal role in susceptibility to malaria infection and associated morbidity ([@bb0130]; [@bb0345]), as well as for metabolism of medications currently on the market ([@bb0380], [@bb0385]).Fig. 2Map showing predicted malaria incidence in Botswana. The map was kindly provided by the Botswana Ministry of Health and Wellness.Fig. 2

To date, relatively little has been published on malaria in Botswana. Here, we summarize those publications and consider current factors affecting malaria elimination in Botswana via a literature review over the past nine decades. We specifically considered studies involving malaria vector species, *Plasmodium* species, and human genetics and how these work in concert to either support or handicap Botswana\'s goal of malaria elimination.

2. Methods {#s0020}
==========

2.1. Article selection {#s0025}
----------------------

Two search engines, PubMed and Google Scholar, were utilized in the review of the widely available literature. All publications were included that matched the selection criteria published between 1 January 1937 and 5 May 2020. The criteria were defined as: any primary data or information in the context of Botswana involving the vectors of malaria, the parasite, or the host\'s interaction with malaria. The search query: "malaria Botswana OR malaria Bechuanaland" was used for PubMed. The search query: "allintitle: Botswana malaria" and "allintitle: Bechuanaland malaria" were utilized for Google Scholar. Each publication was examined for primary data or findings that matched at least one of our three selection criteria. If met, then it was included in the review ([Fig. 3](#f0015){ref-type="fig"} ). The titles of the references from these publications were also scanned for keywords matching our selection criteria and included if they met one of them. Authors included selected publications that did not meet selection criteria at their discretion in order to provide background information on a specific topic, or to further elaborate on a topic when no literature on Botswana were available for reference.Fig. 3Flowchart of the literature search/review strategy.Fig. 3

3. Results and discussion {#s0030}
=========================

3.1. Malaria vectors {#s0035}
--------------------

### 3.1.1. *Anopheles gambiae* {#s0040}

Vectors within the *Anopheles gambiae* sensu lato (s.l.) complex are widely recognized as the primary contributors to malaria transmission in sub-Saharan Africa. Two species within this complex, *An. gambiae* sensu stricto (s.s.) Giles and *An. arabiensis* Patton, are accepted as the most efficient and widespread vectors in this region ([@bb0085]). *Anopheles gambiae* s.s. tends to prefer humid zones, whereas *An. arabiensis* dominates in arid savannas that lack large bodies of water ([@bb0285]). Historically *An. gambiae* s.s., an endophilic and endophagic mosquito, inhabited Southern Africa, though it was never officially identified in Botswana ([@bb0225]). But, aggressive indoor residual spraying (IRS) with dichlorodiphenyltrichloroethane (DDT) is thought to have effectively rendered this species extinct in Botswana, whereas *An. arabiensis* persisted ([@bb0135]). *Anopheles arabiensis* accounts for the majority of malaria transmission within the SADC region ([@bb0430]). To various degrees, *An. arabiensis* when compared to similar vectors within the *An. gambiae* complex is described to as partially zoophilic, exophagic and exophilic. Wide variances in feeding and resting patterns have been recorded, mostly depending upon geographical location ([@bb0340]). These behavioral inconsistences may be controlled genetically rather than environmentally. Karyotype inversions in this species appear to alter resting behavior and anthropophily, allowing for rapid propagation of a trait if selective pressure is applied ([@bb0090]; [@bb0215]). Selection for exophilic phenotypes may account for poor outcomes of IRS campaigns against this vector ([@bb0090]; [@bb0215]). In Botswana, the majority of studies on *An. arabiensis* have been completed in the Northwestern portion of the country. Two studies ([@bb0070]; [@bb0075]) conducted over a 5 year period in the village of Tubu, which is situated along the banks of the Okavango Delta, identified *An. arabiensis* as the primary indoor resting vector ([@bb0075]). They also found it to be highly prevalent at a larval stage ([@bb0070]). Additional studies in this village found samples to be primarily zoophagic, with only 27% of blood fed mosquitos testing positive for human blood ([@bb0070]). A study in seven other districts found a similar average human blood fed frequency of 28% for this species ([@bb0375]). Though, these mosquitoes were collected via pyrethrum spray catches (PSC), suggesting that the aforementioned frequency of 27--28% does not reflect the integration of anthropophily for the vector, given its known behavioral heterogeneity and the likelihood of blood fed mosquitos resting outdoors where PSC would fail to collect them. Additional studies examining the outdoor/indoor resting and feeding behavior of *An. arabiensis* are required to better understand how this vector behaves in Botswana. Studies evaluating post blood meal behavior of all anopheline species via exit window traps or as detailed in [@bb0275], where clay pots are utilized to probe the behavior of outdoor resting vectors, could fill major gaps in the current literature.

*Anopheles arabiensis* infected with *P. falciparum* in Botswana can range between 0 and 3% prevalence in PSC collections, depending on the region, time of year, annual rainfall and human parasite reservoir ([@bb0375]). This delineates *An. arabiensis* as the only vector with confirmed *Plasmodium* infection in the country. This relatively limited prevalence (0--3%) of infected vectors by site contributes to high levels of malaria transmission during peak malaria season and could explain the epidemic nature of the disease in certain areas ([@bb0230]), especially when considering that infected vectors have been shown to congregate in specific areas in other countries ([@bb0200]). *Anopheles arabiensis* has been described in all of Botswana\'s westernmost districts, placing over half of the country\'s populationat at risk to malaria due the presence of malaria infected vectors, given the presence of a *Plasmodium* ridden host ([@bb0350]). Furthermore, the Ministry of Health in Botswana has detected in vivo pyrethroid resistance in this species in all malaria endemic districts, and resistance to DDT in one district ([@bb0320]). Since IRS coverage and availability is relatively high in high risk areas in Botswana ([@bb0445]), *An. arabiensis* should be considered the top priority vector with regards to elimination efforts in the region based upon currently available literature.

### 3.1.2. Anopheles funestus {#s0045}

Surveys in Botswana and surrounding countries have revealed the presence of *An. funestus* s.l., the second most important taxon of malaria vectors in Africa ([@bb0005]; [@bb0080]; [@bb0210]; [@bb0185]; [@bb0375]). This group of species is of particular concern due to documented insecticide resistance and for possibly causing the largest malaria epidemic in South Africa in over 50 years ([@bb0140]). Four studies from the past three decades: a PhD thesis published in 1995, a study from 1998, a survey completed in 2017, and a study published in 2020, confirmed the group\'s presence in Botswana ([@bb0005]; [@bb0185]; [@bb0190]; [@bb0375]). The 1995 thesis identified *An. funestus* s.s., the major vector within the group, in 3 districts and *An. rivulorum* in 1 district ([@bb0005]) ([Fig. 4](#f0020){ref-type="fig"} ). The 1998 study found *An. vaneedeni* in one district ([@bb0190]) ([Fig. 4](#f0020){ref-type="fig"}). The study in 2017 confirmed the presence of *An. parensis* in 4 districts, *An. longipalpis* type C in 2 districts, as well as several non-vector species within the group ([@bb0375]) ([Fig. 4](#f0020){ref-type="fig"}). Of the two species described in the 2017 study, only *An. parensis* was found to have taken a human blood meal. The most recent study in 2020 found *An. longipalpus* type C in one district, and *An. parensis* in two ([@bb0185]) ([Fig. 4](#f0020){ref-type="fig"}). Similar to surrounding countries, *An. funestus* s.l. was assumed to have been reduced to negligible levels with the widespread use of IRS since the 1950s ([@bb0140]). Though, limited data suggests that *An. funestus* s.l. persisted in Botswana as late as 1984 ([@bb0210]). We propose two hypotheses to explain its current presence in the country. The first is that *An. funestus* s.l*.* persisted post IRS implementation, but at negligible levels and has only recently returned to a significant population density. Alternatively, *An. funestus* s.l. migrated from proximal regions in surrounding countries. Nonetheless, non-negligible numbers now exist within several districts. This could prove to be of paramount importance if these mosquitos were found to harbor and effectively transmit *Plasmodium sporozoites* in Botswana, due to evidence of endophilic and limited anthropophilic behavior ([@bb0035]; [@bb0375]). At this time, only one of the species in the group, *An. funestus* s.s.*,* has been thoroughly implicated as a malarial vector in multiple regions of Africa ([@bb0070]; [@bb0080]). Outside of *An. funestus* s.s., *An. vaneedeni* was found to carry *P. falciparum* just across the border in the Mpumalanga and KwaZulu-Natal regions of South Africa ([@bb0045]). Also, sporadic studies have found *An. parensis* and *An. longipalpus* type C to carry *P. falciparum* in other countries, though very little evidence exists to confirm their status as malaria vectors ([@bb0050]; [@bb0280]). Finally, *An. rivulorum* has been incriminated as a vector in Tanzania ([@bb0405]). Further studies assessing transmission of *Plasmodium* by this group of species in Botswana are required in order to determine if it plays a role in disease propagation. If found, Botswana may need to adjust elimination strategies to address this vectors.Fig. 4Published potential/known malaria vectors\' distribution in Botswana ([@bb0005]; [@bb0075]; [@bb0095]; [@bb0185]; [@bb0190]; [@bb0210]; [@bb0290]; [@bb0375]).Fig. 4

### 3.1.3. Other Anopheles {#s0050}

In addition to *An. gambiae* and *An. funestus* species members, several other potential malaria vectors have been identified in Botswana that have been found to harbor malaria parasites in other countries. These include: *An. squamosus, An. pharoensis, An. nili, An. rufipes, An. demeilloni, An. marshalli,* and *An. ziemanni* ([@bb0005]; [@bb0075]; [@bb0095]; [@bb0190]; [@bb0290]). None of these mosquitos have been tested for the presence of *Plasmodium* infection in Botswana, so their role as vectors is not confirmed in the country. Of particular note is the presence of *An. squamosus* and *An. pharoensis*, due to them being found in a 43:1 and 28:1 ratio, respectively, to *An. arabiensis* when collected via nighttime outdoor carbon dioxide traps in villages on the western side of the Okavango Delta ([@bb0095]; [@bb0290]). To date, neither of these mosquitos has been implicated in the transmission of malaria in Botswana. However, substantial evidence in other African countries points to both of these mosquitoes as potential secondary vectors ([@bb0055]; [@bb0355]). Their relative abundance and attraction to carbon dioxide in outdoor settings may indicate that these mosquitos are generally exophagic, possibly even more so than *An. arabiensis*. Additionally, a novel study in the Sahel region of Mali demonstrated that both of these vectors, after taking human blood meals, potentially travel 100--200 km ([@bb0160]) via air currents. This is of particular importance in districts that experience sporadic epidemics, if the mosquitoes in Botswana were found to behave in a similar manner. Furthermore, the study from Mali found that *An. arabiensis* did not travel via the same mechanism, even though it is a known local vector within that study region ([@bb0160]). Further research analyzing the infection status of *An. squamosus* and *An. pharoensis*, as well as their migratory behavior, are needed to truly understand the possible role these mosquitos play in malarial transmission in Botswana. Of the other seven potential vectors found in Botswana, *An. ziemanni* has been noted in small numbers in two unrelated studies in one district ([@bb0095]; Pachka et al) ([Fig. 4](#f0020){ref-type="fig"}). *Anopheles nili* and *An. rufipes* were reported in the previously mentioned thesis ([@bb0005]). *Anopheles demeilloni* and *An. marshallii* were identified as a minor species via indoor PSC in a study looking for *An. arabiensis* ([@bb0075])*.* All of these *Anopheles* species have been found to carry *Plasmodium* in other countries ([@bb0025]; [@bb0055]; [@bb0110]; [@bb0210]; [@bb0360]; [@bb0365]; [@bb0405]). As these species were found in minute quantities compared to other vectors, there is a low likelihood of them contributing significantly to malaria transmission. It is important to note that very few published entomological studies completed in the last 25 years in Botswana even assessed the presence of additional vectors outside of *An. gambiae* s.l.. This may have resulted in significantly underrepresenting the true distribution and density of these mosquitoes.

### 3.1.4. Non-vector anophelines {#s0055}

Additional species of *Anopheles* are present in Botswana, though their capacity as vectors is not confirmed in Africa. However, disregarding these species in future vector studies should be considered erroneous due to the potential of emerging vectorial behavior or ability. In [Box 1](#b0005){ref-type="boxed-text"} we include the most up to date list of *Anopheles* species found in Botswana since 1935.Box 1List of all 31 anophelines that have been identified in Botswana since 1935 (Abdulla-Khan, 1995; Abdulla-Khan et al., 1998; Chirebvu et al., 2016; Cornel et al., 2018; Kgoroebutswe et al., 2020; Koekemoer et al., 1998; Kyalo et al., 2017; Pachka et al., 2016; Tawe et al., 2017). \*Underlined species are vectors in Africa.Unlabelled Table[*An. arabiensis, An. demeilloni, An. funestus* s.s.*, An. longipalpis, An. marshallii, An. parensis, An. pharoensis, An. rivulorum, An. squamosus, An. vaneedeni, An. ziemanni, An. nili,*]{.ul}*An. argentolobatus, An. caliginosus, An. coustani, An. distinctus, An. leesoni, An. listeri, An. pretoriensis, An. quadriannulatus, An. rhodesiensis, An. rufipes, An. seretsei, An. tchekedii, An. tenebrosus, An. walravensi, An. wellcomei ugandae, An. theileri, An. implexus, An. kingi, An. maculipalpis.*Alt-text: Box 1

3.2. *Plasmodium* species {#s0060}
-------------------------

### 3.2.1. Malaria parasites found in Botswana {#s0065}

Of the five species of Plasmodia generally accepted to exploit humans for schizogony ([@bb0020]), the three most predominant in Africa have been found in Botswana: *P. falciparum, P. vivax* and *P. malariae* ([@bb0245]). Given the presence of *P. vivax,* a small reservoir of *P. ovale* is also likely, and has been found in surrounding countries ([@bb0015]; [@bb0125]; [@bb0400]; [@bb0420]). Here we discuss two of these species, *P. falciparum* and *P. vivax*, due to their prevalence, prognosis, and inclusion in malaria treatment guidelines in Botswana ([@bb0315]).

*Plasmodium falciparum*, best known for being the etiological factor in malaria *tropica,* contributes to the majority of the malarial morbidity and mortality in Africa ([@bb0445]) and this is reflected also in Botswana. Rapid progression of the disease makes immediate diagnosis and treatment of this species the primary variable for good patient outcomes ([@bb0240]).

Of the other two *Plasmodium* species identified, *P. vivax* is the most prevalent. [@bb0245] demonstrated that, in asymptomatic children, it is far more prevalent than even *P. falciparum* at an average national prevalence of 4.66% and 0.16%, respectively ([@bb0245]). These data contradict the official data from Ministry of Health and Wellness where malaria in Botswana is reported being almost 100% *P. falciparum* ([@bb0445]). However, it important to note that data reported by WHO are on symptomatic patients based on RDT positivity, while research outputs ([@bb0245]) are on the asymptomatic reservoir analyzed through molecular techniques. This is not surprising given the differences in life cycles of the two parasites, which directly impacts the severity of symptoms depending upon the species as well as the likelihood of patients presenting themselves for treatment ([@bb0020]). In fact, subjects infected with *P. falciparum* are far more likely to develop symptomatic malaria in the low endemic context of Botswana, where malaria immunity is generally absent or very low ([@bb0380]). Biological determinants were long thought to limit *P. vivax*\'s pathogenicity. However, global attention has shifted towards this organism due to reports on fatalities and poor patient outcomes if radical cure is not achieved ([@bb0035]; [@bb0155]). High levels of Duffy negativity in Africa, an antigen originally thought to be essential for erythrocyte invasion, initially led to *P. vivax* being discarded as a pathogen of major concern in the continent. However, international literature now points to *P. vivax* having the ability to invade red blood cells, no matter the Duffy status ([@bb0155]; [@bb0305]). In Botswana, where Duffy negativity rates are not fully known, but estimated between 30 and 80% ([@bb0150]), asymptomatic *P. vivax* prevalence is quite high ([@bb0245]). Nevertheless, there is no evidence of symptomatic *P. vivax* infections or confirmed cases of *P. vivax* relapse. Though, a literature review on imported cases from Botswana to the United States of Ameria in the last 20 years revealed sporadic cases of *P. vivax* and unknown *Plasmodium* spp., other than *P. falciparum*, thus confirming a low but historical circulation of non-*falciparum* parasites ([@bb0060]; [@bb0105]; [@bb0115]; [@bb0145];[@bb0410]). The vectors that carry *P. vivax* in the country have not been identified, but may include *An. arabiensis*, members of the *An. funestus* group*,* and *An. pharoensis*, based upon data from other African countries ([@bb0155]).

Only one publication has described malarial parasites outside of *P. falciparum* in Botswana ([@bb0245]). Studies quantifying the current human parasitic reservoir, as well as identifying the primary vector of this species, are needed in order to direct medical interventions.

### 3.2.2. Diagnostic methods {#s0070}

Identification of the *Plasmodium* species via microscopy and/or molecular methods is of the utmost importance in order to ensure proper treatment and patient outcomes ([@bb0435]). Historically, the vast majority of malaria in Botswana was diagnosed based upon symptoms alone. Only the turn of the millennia saw a push for the widespread implementation of microscopy and rapid diagnostic tests (RDTs) in the country ([@bb0235]). As of 2013, 89% of diagnoses were made via one of these two diagnostic methods, in comparison to 6% six years earlier. The latter of these two tests is preferred by health workers due to its ease of use and the lack of trained microscopists ([@bb0235]). For example, between 2013 and 2014, 94% of patients were diagnosed via RDT and 6% via microscopy ([@bb0235]). Though, RDT stock outs have been noted by the Ministry of Health ([@bb0040]). Overall, the number of positive RDTs confirmed by microscopy continues to decline due to diagnostic noncompliance, despite recommendations that all positive samples undergo microscopy to confirm *Plasmodium* species and parasitemia ([@bb0235]). The lack of microscopy implementation stands as a barrier for elimination efforts, especially due to recent studies demonstrating a much higher prevalence of alternative *Plasmodium* species, particularly *P. vivax*, than originally expected ([@bb0245]). This is noteworthy because many RDTs utilized within the country lack the capacity to identify species other than *P. falciparum* and only indicate a mixed infection. This makes it difficult for clinicians to tailor treatment to specific species, which can cause relapse.

### 3.2.3. Malaria treatment {#s0075}

Until 1997, chloroquine was the first line treatment for uncomplicated *P. falciparum* malaria in Botswana, but was replaced with sulfadoxine-pyrimethamine due to anecdotal reports of reduced efficacy ([@bb0040]). Circa 2006, drug efficacy reports showed high failure rates in patients treated with *sulfadoxine*-pyrimethamine ([@bb0040]), which led to confirmed cases of *P. falciparum* by RDT or microscopy being treated with artemether-lumefantrine ([@bb0040]). Additionally, a single dose of primaquine as a gametocytocide, in uncomplicated cases, was adopted in 2010 in accordance with WHO guidelines ([@bb0040]). Until 2015, quinine was the chemotherapy of choice for severe malaria. Parenteral artesunate was then adopted in line with WHO recommendations ([@bb0040]; [@bb0315]; [@bb0435]). No medication shortages were noted by the Ministry of Health ([@bb0315]).

Unlike *P. falciparum*, *P. vivax* requires treatment to clear both the blood infection and for radical cure of liver hypnozoites that may cause relapse. This can only be achieved via a fourteen day course of primaquine ([@bb0030]). This medication can result in haemolytic toxicity in individuals that are G6PD deficient when administered the WHO recommended dose of 0.25--0.5 mg/kg over the two week period ([@bb0435]). In a setting such as Botswana, where G6PD deficiency rates are relatively low, phenotyping patients prior to treatment with the two week course of primaquine may be required in order to avoid malpractice and to better align with national guidelines ([@bb0250]; [@bb0315]). Currently, testing for G6PD is not conducted, nor are patients treated with full two week courses of primaquine due to a lack of point of care diagnostics for G6PD and RDTs that effectively identify *P. vivax* ([@bb0315]).

### 3.2.4. Drug resistance surveillance {#s0080}

A recent report on drug resistance markers in *P. falciparum* demonstrated that the parasite harbors certain variation in several of the genes analyzed. In the study, 95.8% of samples showed N86 polymorphism at *Plasmodium falciparum multidrug resistance 1* gene (*pfmdr1*) ([@bb0380], [@bb0385]) known to confer sensitivity to 4-aminoquinolines ([@bb0155]) (chloroquine and amodiaquine) but also associated to a reduced sensitivity to lumefantrine ([@bb0425]). This suggests that a similar situation to that seen in Malawi ([@bb0195]) has unfolded in Botswana with regards to chloroquine. More importantly, *P. falciparum* may be generally tolerant to lumefantrine, which is one of the compounds utilized in first line treatment together with the highly efficacious artemether. The same study found two synonymous mutations - V555V and R513R - in the propeller domain of the *P. falciparum Kelch13* gene (*pfk13*) ([@bb0380], [@bb0385]) which is implicated in the resistance to artemisinin. It should be noted that neither of these genetic variants were associated with a delayed parasite clearance phenotype. However, this indicates that molecular assessment and continuous surveillance of the *pfk13* and *pfmdr1* genes as drug resistance markers in Botswana is of paramount importance. No documented drug surveillance conducted by local Ministry of Health and Wellness for *P. vivax* has been reported in Botswana.

3.3. Human genetics {#s0085}
-------------------

Botswana is home to a population that arises from two distinct ancestries, the Bantu and Khoisan speaking peoples, with remarkably diverse genetic and linguistic backgrounds ([@bb0330]). It is generally accepted that these two populations converged approximately 2000 years ago with the arrival of the Bantu speaking peoples from the North, which contributed to the diversification and admixture between the two ancestral populations ([@bb0330]). Since malaria is acknowledged to have applied significant selective pressure to humans ([@bb0205]), genetic differences in Duffy status, haemoglobin S frequency and G6PD deficiency have been noted based upon geographic location and ancestral background ([@bb0170]; [@bb0175]; [@bb0250]; [@bb0310]). This is especially pertinent since the Bantu originated from a highly endemic malaria setting, whereas the Khoisan were likely only exposed to sporadic outbreaks that did not apply chronic selective pressure and therefore lack of malaria-resistance alleles ([@bb0220]; [@bb0335]). Additionally, the recent imposed sedentarism to the traditionally n*omadic hunter-gatherers* Khoisan communities of the Kalahari region of Botswana ([@bb0180]; [@bb0415]; [@bb0165]) may also have an impact on malaria acquisition risk. Recent reports have also indicated that this genetic diversity plays a significant role in pharmacogenetics pertaining also to antimalarial drugs used in Botswana ([@bb0380], [@bb0385]). In Botswana, the peculiar genetic admixture between these two populations clusters specific genotypes more than other Southern African countries ([@bb0325]). In particular, this genetic structure has potential implications on susceptibility and resistance to infectious diseases and treatment outcomes ([@bb0325]; [@bb0380], [@bb0385]; [@bb0390]).

Of final note, the original occupants of the region, the Khoisan, appear to have been occasionally exposed to malaria "in exceptionally rainy seasons" ([@bb0220]) and had traditional medicines to treat its symptoms. A report from the 1930s described a tribe of Khoisan that had lost many of its children to the disease during a flood year. This same group utilized the roots of *Tarchonanthus camphoratus* to treat the fevers and headaches associated with malaria ([@bb0220]).

### 3.3.1. Sickle cell anemia {#s0090}

In many African countries overall childhood mortality is high; but in children with sickle cell disease it is higher still (50--90%). Though, limited temporal data exists on the continent ([@bb0120]). The frequency and distribution of the haemoglobin S (HbS) allele, and its overlap with that of malaria, acts as the geographical confirmation of the malaria hypothesis for selection of this allele ([@bb0130]). In Botswana, the frequency of the HbS allele is estimated to be between 0 and 2%, though this is a very rough estimation given a lack of data for the region ([@bb0300]). However, these limited data support a distribution of this allele that generally reflects the malaria endemicity in the country, with higher frequencies seen in the North and lower in the South. Lastly, a survey conducted in 1967 was unable to identify any sickled cells in a sample of Khoisan and Bantu individuals in the Kgalagadi ([@bb0170]). Additional surveys would be needed in order to measure HbS allele frequency in Botswana according to the geographical context and malaria endemicity.

### 3.3.2. G6PD deficiency {#s0095}

Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is common in Africa due to high levels of selective pressure from *Plasmodium* and conferred advantage against clinical malaria in heterozygous females ([@bb0345]). In Botswana, data exist on the frequency of the African G6PD A- allele. Early publications from the 1960s and 1970s could only find relatively low G6PD deficiency in the Khoisan peoples they studied (1--5% with a higher percentage in the Northwest), and surprisingly no deficiency in the Bantu ([@bb0170]). This finding is somewhat congruent with a recent study that discovered the G6PD deficiency rate in a pattern that peaks in the Northwest (3.37%) and decreases steadily with latitude until reaching its minimum in the Southeast of the country ([@bb0250]). Interestingly, these latter results reflect the distribution of malaria endemicity in Botswana. Glucose-6-Phosphate Dehydrogenase testing should be considered if radical cure for *P. vivax* via primaquine is ever utilized in Botswana, especially with regards to the use of a point of care diagnostic tool for G6PD deficiency, prior to treatment. It is worth noting that single dose primaquine, that is gametocytocidal for *P. falciparum,* has been shown to be safe for G6PD deficient persons ([@bb0435]).

### 3.3.3. Duffy {#s0100}

Very little published data exists on the Duffy status of individuals in Botswana relative to their respective genetic backgrounds. In general, literature shows that there is a lack of the African-specific Duffy negativity among Khoisan ([@bb0265]; [@bb0295]; [@bb0335]), consistent with the evolutionary history of this population. While, the Bantu expanded to East and Southern Africa from a region between southern Nigeria and Cameroon ([@bb0260]) where malaria was (and is still) endemic, which correlates with having Duffy negativity at a very high rate. Thus, Duffy negativity rate in Botswana mostly depends from the admixture history between the two main populations. One survey based on 79 unrelated subjects showed that 75.9% of North-eastern individuals from Botswana were Duffy negative (Fy(a-b-)) ([@bb0065]). Another study by these authors found a similar frequency of the same phenotype in individuals from the Bakgalagadi tribe, which consists of peoples of mostly Bantu origin in the Southwest of the country ([@bb0175]). A recent global report on Duffy, which summed data from several surrounding countries, predicted a gradual decline in the frequency of the negative phenotype in the Southwest direction, especially as one crosses the border into Namibia ([@bb0150]). Given that the Bantu peoples originated from a region with near 100% Duffy negativity in Central-West Africa ([@bb0150]) and are found in increasing quantities in the Northeast of Botswana, this matches the ethnographic distribution in Botswana and surrounding countries. This hypothesis also aligns with a model recently proposed in the literature on the origin of *P. vivax* in West Africa ([@bb0310]), where Duffy negativity is at its highest level, then decreasing in frequency from the epicentre south-eastwards. Despite being originally thought to provide protection against *P. vivax*, Duffy negative individuals appear to still be at risk for *P. vivax* infection ([@bb0155]), since it is now proven that for red cell invasion by *P. vivax* Duffy is not an absolute requirement ([@bb0305]). However, there is no available data on whether *P. vivax* infected subjects from Botswana are Duffy-negative or Duffy-positive.

4. Malaria and COVID-19 {#s0105}
=======================

As we write, the SARS-CoV-2 epidemic is ongoing in Botswana. The COVID-19 pandemic has forced countries to prioritize containment and mitigation measures such as social distancing and lockdowns as part of the primary response in reducing the number of cases. These measures have resulted in readjustment of resources that were initially allocated towards routine public health programs such as immunization and surveillance. Given that majority of malaria cases occur in Sub-Saharan Africa, one of the poorest regions in the world, the further readjusting of already limited resources is likely to put a strain on Governments in the provision of quality healthcare.

Furthermore, the similarity of the most symptoms associated between COVID-19 and malaria (such as fever and fatigue) has the potential to misdiagnose individuals. This places further strain on healthcare resources. It is important to note that all efforts towards malaria elimination should still continue in order to not erode all efforts and milestones that have been achieved.

5. Conclusions {#s0110}
==============

Botswana has made massive strides over the past 50 years with malaria control initiatives and has come remarkably close to elimination with the turn of the millennia. However, an increase of more than 80% of malaria cases between 2015 and 2017 led to the WHO placing Botswana in the top three most concerning E-2020 countries in 2018 ([@bb0440]). This review surveyed the literature describing three major biological factors that impact malaria in Botswana: vector diversity, *Plasmodium* species, and host genetics. To date, a very limited number of pertinent primary publications assess these three factors in Botswana. Additional studies that describe the behavior of primary vectors and the vectorial capacity of other mosquito species, in concert with research assessing and characterizing the parasite reservoir, are warranted in order to direct elimination efforts and to understand transmission in Botswana. Finally, future studies into the unique and diverse genetic background of Batswana should also be considered for insights into its complex interaction with malaria. Overall, these three major biological factors should be considered in order to craft an effective elimination strategy for the country.
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